Journey Medical Past Earnings Performance
Past criteria checks 0/6
Journey Medical's earnings have been declining at an average annual rate of -9.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 12.2% per year.
Key information
-9.3%
Earnings growth rate
-1.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 12.2% |
Return on equity | -167.8% |
Net Margin | -31.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Oct 03Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Sep 14Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
May 06Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Revenue & Expenses Breakdown
How Journey Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 58 | -18 | 40 | 11 |
30 Jun 24 | 78 | 1 | 37 | 13 |
31 Mar 24 | 80 | -4 | 39 | 13 |
31 Dec 23 | 79 | -4 | 44 | 8 |
30 Sep 23 | 80 | -12 | 48 | 10 |
30 Jun 23 | 61 | -39 | 55 | 11 |
31 Mar 23 | 63 | -38 | 58 | 12 |
31 Dec 22 | 74 | -30 | 59 | 11 |
30 Sep 22 | 75 | -41 | 61 | 9 |
30 Jun 22 | 79 | -41 | 56 | 7 |
31 Mar 22 | 76 | -46 | 48 | 18 |
31 Dec 21 | 63 | -44 | 40 | 17 |
30 Sep 21 | 59 | -20 | 31 | 15 |
30 Jun 21 | 49 | -9 | 26 | 14 |
31 Mar 21 | 45 | 4 | 23 | 0 |
31 Dec 20 | 45 | 5 | 22 | 0 |
31 Dec 19 | 35 | 4 | 19 | 0 |
Quality Earnings: DERM is currently unprofitable.
Growing Profit Margin: DERM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DERM is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.
Accelerating Growth: Unable to compare DERM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DERM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: DERM has a negative Return on Equity (-167.82%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 21:59 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Journey Medical Corporation is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Scott Henry | Alliance Global Partners |
Kalpit Patel | B. Riley Securities, Inc. |
Brandon Folkes | Cantor Fitzgerald & Co. |